Sune Nygård is the Senior International Medical Director, currently supporting MASH projects and the MASH therapeutic area development within Medical & Science in Novo Nordisk A/S. He has extensive experience from early to late phase clinical drug development as well as expertise in precision medicine and diagnostic test development. Sune is an MD from the University of Copenhagen, Denmark, and holds a board certification in pathology and a PhD in molecular disease biology and biomarker development.